Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 58

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 58
---
 irreparable, double-strand DNA breaks and other cellular
damage upon direct impact – within a very short distance. Accordingly, we believe that alpha radiation has several significant potential
advantages for use in cancer radiotherapy, including a high relative biological efficiency (potentially enabling it to destroy tumor cells
with administration of lower levels of radiation), imperviousness to factors such as hypoxia, and a very well-defined range of travel
with limited collateral damage. Nonetheless, its use has also been limited precisely due to alpha’s extremely short particle range
in living tissue, as the range of less than 100 μm is insufficient to provide meaningful clinical utility.

The Alpha DaRT technology employs a series of
radioactive sources that are embedded with Radium-224 to enable a controlled, intratumoral release of alpha-emitting atoms which diffuse
and decay throughout the tumor, seeking to kill cancerous cells with localized precision, while penetrating deeper into the tumor than
can otherwise be reached by the limited ranges of the alpha particles themselves. Due to the inherent limited range of the alpha particles,
we believe that the Alpha DaRT technology has the potential to deliver powerful and localized precise killing impact to the tumor without
damage to surrounding healthy tissue. By combining the innate relative biological effectiveness and short range of alpha particles in
a single-use disposable form, we believe that the Alpha DaRT could address tumors that have otherwise demonstrated poor response to radiation
therapy or other standards of care, with the potential to apply to a wide range of tumors and clinical settings.

<div align='center'>2</div>

We evaluated the feasibility, safety and efficacy
of the Alpha DaRT technology in a first-in-human study of locally advanced and recurrent SCC cancers of the skin and head and neck, the
results of which were subsequently published in the International Journal for Radiation Oncology, Biology, Physics and which elicited
a positive editorial reaction in the same journal. Efficacy was evaluated in 28 tumors of the skin and head and neck, and results showed
that Alpha DaRT achieved a >78% complete response rate. The trial was conducted in an elderly (median age = 80.5 years) and largely
pre-treated patient population, with 42% of the target lesions, including non-evaluated lesions, having already received radiation therapy.
The Alpha DaRT was generally well-tolerated, with limited local toxicity and no systemic toxicity. Following these initial positive results,
we substantially expanded our clinical evaluations in later trials to a much wider